Findings from a large, multi-cohort study suggest the genomic test can improve care for lung nodule patients with inconclusive bronchoscopy results

SOUTH SAN FRANCISCO, Calif., July 13, 2022--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced that new data published today in PLOS ONE show that the company’s Percepta Genomic Sequencing Classifier (GSC) is highly accurate in re-classifying lung cancer risk among patients with lung nodules whose bronchoscopy results are inconclusive. The authors also conclude that, based on findings from the large, multi-cohort study, use of the genomic test could enable a significant portion of patients to avoid unnecessary and invasive diagnostic procedures and offer the potential for earlier diagnosis.

"Quickly and accurately determining whether lung nodules identified through screening or incidentally are benign or malignant is critical to improve patient outcomes, but is often challenging. Physicians frequently use bronchoscopy to evaluate potentially cancerous lung nodules because it is less invasive than surgery, however, many times this procedure produces inconclusive results, leaving physicians and patients without clear guidance about what to do next," said Bill Bulman, M.D., Veracyte’s medical director for lung cancer. "The findings from this study suggest that the Percepta GSC provides accurate, objective information that can help resolve this challenge."

Researchers evaluated the ability of the Percepta GSC to accurately classify risk of malignancy (ROM) in a blinded, independent set of 412 samples from lung nodule patients who were included in one of three, large study cohorts (AEGIS I/II and the Percepta Registry study). Each sample was classified pre-bronchoscopy as low, intermediate or high ROM and subsequently had a bronchoscopy result that was inconclusive.

Among patients with a pre-bronchoscopy intermediate ROM – which accounts for the largest group of lung nodules undergoing bronchoscopy – the Percepta GSC re-classified a total of 41% to either low or high risk. Patients in this cohort were re-classified to low risk with a 91% negative predictive value (NPV) or up-classified to high-risk with a 65% positive predictive value (PPV). Additionally, among pre-bronchoscopy low-risk nodules, the Percepta GSC down-classified 54.5% to very low risk with 100% sensitivity, indicating no false negatives, and a >99% NPV, and the test up-classified 27.3% of high-risk lesions to very-high risk with a specificity of 91.2% and 91.5% PPV. Across all pre-bronchoscopy risk groups, the Percepta GSC re-classified nearly 40% (39.1%) of patients into a different category of cancer risk.

The researchers also concluded that if the Percepta GSC results were used in this cohort of patients, 50% of those with low or intermediate pre-bronchoscopy ROM and benign lesions, as well as 29% of those with malignant lesions, who underwent additional invasive procedures could have avoided them.

"By accurately classifying lung nodules that have inconclusive bronchoscopy results, the Percepta GSC can help patients avoid unnecessary invasive procedures, and help ensure earlier diagnosis and more timely treatment for those at high risk of cancer," said Giulia C. Kennedy, Ph.D., Veracyte’s global chief scientific officer and chief medical officer.

The Percepta GSC stratifies the risk of primary lung cancer across all pre-bronchoscopy risk groups to guide patient management when bronchoscopy is inconclusive. Veracyte developed the second-generation genomic test using RNA whole-transcriptome sequencing and machine learning, and by leveraging novel "field of injury" science through which genomic changes associated with lung cancer can be found in the airways of current or former smokers. The Percepta GSC is performed utilizing a sample collected from a brushing of the patient’s main lung airway during a bronchoscopy. The test is covered by Medicare.

Veracyte (Nasdaq: VCYT) is a global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions. Our growing menu of advanced diagnostic tests help patients avoid risky, costly procedures and interventions, and reduce time to appropriate treatment. Our tests address eight of the 10 most prevalent cancers by incidence in the United States. In addition to making our tests available in the United States through our central laboratories, our exclusive license to a best-in-class diagnostics instrument positions us to deliver our tests to patients worldwide through laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to the Percepta Genomic Sequencing Classifier (GSC). Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "suggest," "may," "will" "prospective" and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. An example of a forward-looking statement includes, among others, that the Percepta GSC can help physicians accurately risk stratify lung nodules that receive inconclusive diagnostic results from bronchoscopy. Additional factors that may impact these forward-looking statements can be found under the caption "Risk Factors" in our Annual Report on Form 10-K filed with the SEC on February 28, 2022, and our subsequent quarterly reports on Form 10-Q. A copy of these documents can be found at the Investors section of our website at www.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, Veracyte specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Veracyte, the Veracyte logo, and Percepta are registered trademarks of Veracyte, Inc. and its subsidiaries in the U.S. and selected countries. The Percepta GSC is available as part of Veracyte’s CLIA-validated laboratory developed test (LDT) service. This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220713005843/en/

Investors: Shayla Gorman Director, Investor Relations investors@veracyte.com 619-393-1545

Media: Tracy Morris Vice President, Global Corporate Communications tracy.morris@veracyte.com 650-380-4413

University Health doctor explains medication President Joe Biden is using to treat COVID-19

Not everyone should take Pfizer's COVID-19 antiviral drug, doctors say

Story at a glance Researchers from University College London conducted an umbrella review of past meta-studies and systematic analyses of depression’s relationship to serotonin. For years, a chemical imbalance of serotonin has been widely viewed as the culprit for depression, resulting in the widespread use of antidepressants. The study published this week in the journal…

The FDA bestows a Fast Track designation to Olema's (OLMA) novel pipeline candidate, OP-1250, for the treatment of ER+/HER2- metastatic breast cancer. Stock up.

Frisbie Memorial Hospital CEO Tim Jones said the tragic death of Rick Semo was not a one-off case of violence at the hospital.

Booster shots of the coronavirus vaccine for people younger than 50 are on hold as the Biden administration tries to accelerate a fall vaccination campaign using reformulated shots that target the now-dominant omicron subvariants, according to federal health officials. Officials are hoping vaccine makers - Moderna and Pfizer and its German partner, BioNTech - are able to make the updated shots available as soon as early to mid-September instead of later in the fall, said three officials who spok

The numbers of new cases logged by the Florida Health Department isn't changing much, but sewage levels belie that picture.

Lifeguards watch as beach-goers enjoy the surf at Smith Point County Park, a Long Island beach, on Friday, July 15, 2022. (AP Photo/John Minchillo) An Alabama man who planned to spend a leisurely day swimming with his family while vacationing on the Gulf Coast in Florida ended up having part of his leg amputated after contracting an insidious flesh-eating bacteria through a small cut that had been healing. William Pledger, 75, was enjoying the warm weather with his relatives in Little Sabine Bay

“(The Minnesota pharmacist’s) actions put her life in danger and also affected those who were in need of morphine sulfate but instead received a tainted, watered-down medication,” an agent said.

In an interview with Barron's, Dr. Anthony Fauci said Covid-19 cases like President Biden's, where a maximally vaccinated person still gets infected, are "very commonly experienced now."

When Alex Belth's wife Emily was 22, she developed Crohn’s, an autoimmune disease. Here he shares how he's navigated his role as a caregiver.

President Joe Biden has "tested positive for COVID-19. He is fully vaccinated and twice boosted and experiencing very mild symptoms," according to Karine Jean-Pierre, the White House press secretary, in a statement. "The president is fully vaccinated and twice-boosted, so I anticipate that he will respond favorably, as most maximally protected patients do," Kevin O'Connor, the president's physician, wrote. Biden is said to have "mild symptoms." BA.5 is causing infections (and reinfections) to su

The push toward healthier living is loading another device onto the wrist, thanks to two Bay Area companies. Verily Life Sciences and iRhythm Technologies Inc. said Friday the Food and Drug Administration cleared the Zio Watch and an accompanying system to help monitor atrial fibrillation — shorthanded as AFib — the most common type of an irregular heartbeat, or arrhythmia. The device will be rolled out by San Francisco-based iRhythm (NASDAQ: IRTC) next year in a limited way as it and South San Francisco-based Verily gather more clinical evidence and ways to use the watch, and then only by prescription.

Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) stocks have bucked the bear market trend so far this year, gaining 6% and 20% respectively, compared to the S&P 500's loss of more than 17%. Analysts at Morgan Stanley recently noted that obesity has the potential to become the next blockbuster pharma category, reaching a value of $54 billion in 2030. The main reason for that projection is that treatment trends are showing more of a focus on upstream causes of diabetes and cardiovascular disease, rather than on treating the resulting diseases.

Alana "Honey Boo Boo" Thompson will undergo a non-surgical weight-loss procedure this summer, her manager confirmed to TODAY.

Although we are seeing higher cases within the gay community, monkeypox is not just exclusive to men who have sex with other men.

Ozzy Osborne also gave an update on his health while attending Comic-Con in San Diego on Friday

State lawmakers will convene Monday for a 21-day session in which the fate of abortion access in Indiana will likely be decided.

Police officer Emma Capper previously beat breast cancer

(Reuters) -The rapidly spreading monkeypox outbreak represents a global health emergency, the World Health Organization's highest level of alert, WHO Director-General Tedros Adhanom Ghebreyesus said on Saturday. The WHO label - a "public health emergency of international concern (PHEIC)" - is designed to trigger a coordinated international response and could unlock funding to collaborate on sharing vaccines and treatments. "Although I am declaring a public health emergency of international concern, for the moment this is an outbreak that is concentrated among men who have sex with men, especially those with multiple sexual partners," Tedros told a media briefing in Geneva.